Tirzepatide: Complete Guide to Dosage, Mechanism, and Weight Loss Results

Tirzepatide is currently the most effective weight-loss medication that has been through large-scale clinical trials. Its results — up to 21% mean body weight reduction in some trial arms — exceed anything previously seen in a pharmacological agent for obesity. In a direct 2025 head-to-head comparison with semaglutide (SURMOUNT-5), it produced 47% greater relative weight loss.

But this is a prescription medicine requiring medical supervision, an escalating injection protocol, and careful monitoring. This guide covers everything you need to make an informed conversation with a doctor.

---

1. What is Tirzepatide?

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist — sometimes called a "twincretin" because it activates two separate incretin hormone pathways simultaneously. It is a 39-amino acid synthetic peptide, developed by Eli Lilly, with a half-life of approximately five days — enabling once-weekly dosing.

It is sold under two brand names:

• Mounjaro — approved by the FDA in May 2022 for type 2 diabetes (T2D)
• Zepbound — approved by the FDA in November 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity

The FDA has also approved tirzepatide (Zepbound) for obstructive sleep apnoea (OSA) in adults with obesity — granted in December 2024 — making it the first pharmacological treatment ever approved for OSA.

UAE availability: Mounjaro has been registered with MOHAP and available through licensed UAE pharmacies (including Aster, Life Pharmacy, and Boots UAE) since late 2023–2024. It is a prescription-only medicine. Grey-market or compounded tirzepatide is illegal in the UAE under Federal Law No. 4 of 1983 governing pharmaceuticals.

"Tirzepatide doesn't just do what semaglutide does — it does something complementary at the same time. That combination appears to be why the numbers are meaningfully better."

---

2. How it works

Tirzepatide's exceptional results come from simultaneously activating two distinct receptor pathways that work through overlapping but non-redundant mechanisms.

GLP-1 receptor agonism

The glucagon-like peptide-1 (GLP-1) receptor agonist component is responsible for:

• Glucose-dependent insulin secretion — stimulates pancreatic beta cells to release insulin when blood glucose is elevated
• Glucagon suppression — reduces glucagon from alpha cells, lowering hepatic glucose output
• Central satiety signalling — activates GLP-1 receptors in the hypothalamus and brainstem to reduce appetite and food intake
• Gastric emptying delay — slows the rate at which food leaves the stomach, reducing post-meal glucose spikes and extending satiety

GIP receptor agonism

The glucose-dependent insulinotropic polypeptide (GIP) receptor agonist component adds distinct effects:

• Additive insulin secretion — works through a separate receptor to amplify glucose-stimulated insulin release alongside GLP-1 signalling
• Adipose tissue remodelling — GIPR activation in adipose tissue promotes lipid utilisation and reduces visceral lipotoxicity, addressing metabolic dysfunction that contributes to insulin resistance
• Independent CNS appetite suppression — GIP receptors are expressed at the arcuate nucleus and on vagal afferents, providing appetite regulation through a pathway separate from GLP-1's action
• Bone metabolism protection — GIP has an anabolic role in bone that may partially offset the potential bone density effects of rapid weight loss
• Glucagon preservation in hypoglycaemia — unlike GLP-1, GIP may support glucagon release when blood glucose falls too low, contributing to a more favourable hypoglycaemia profile

Why dual agonism outperforms GLP-1 alone

GIP and GLP-1 receptors are co-expressed in overlapping but distinct neuronal populations across the hypothalamus and brainstem. When both are activated simultaneously, the net anorectic (appetite-suppressing) signal is greater than either pathway can produce alone. The two pathways also appear to mitigate receptor tolerance: chronic GLP-1 stimulation can lead to receptor internalisation and reduced response, while GIPR activation via a complementary mechanism helps sustain the overall effect over time.

This is the mechanistic basis for why tirzepatide outperforms selective GLP-1 receptor agonists like semaglutide in head-to-head trials.

---

3. Research summary

Research level: Strong. Tirzepatide has one of the most extensive clinical trial programmes ever conducted for a weight-loss or diabetes medication. The SURPASS programme (T2D) and SURMOUNT programme (obesity) together span thousands of patients across multiple Phase 3 RCTs. Direct head-to-head comparison with semaglutide 2.4mg was completed in 2025.

SURPASS programme — Type 2 diabetes

| Trial | Comparator | Key outcomes | |-------|-----------|-------------| | SURPASS-1 | Placebo (monotherapy) | HbA1c −1.87–2.07%; weight −7.0–9.5 kg | | SURPASS-2 | Semaglutide 1mg | Tir 15mg vs sema 1mg: HbA1c −2.30% vs −1.86%; weight −11.2 kg vs −5.7 kg | | SURPASS-3 | Insulin degludec | Weight −13.9 kg (tir 15mg) vs +2.3 kg (insulin) | | SURPASS-4 | Insulin glargine (high CV risk) | Fewer hypoglycaemic events; superior HbA1c reduction | | SURPASS-5 | Added to insulin glargine | Significant HbA1c and weight reduction added on top of basal insulin |

SURMOUNT programme — Obesity and weight management

| Trial | Population | Key outcome | |-------|-----------|-------------| | SURMOUNT-1 (Jastreboff 2022, NEJM) | n=2,539 without T2D, 72 weeks | 15mg: −20.9% weight; 37% lost ≥25% of body weight; placebo −3.1% | | SURMOUNT-2 | T2D + obesity | −15.7% weight at 15mg | | SURMOUNT-3 | Intensive lifestyle lead-in → tir | −26.2% weight from original baseline (lifestyle + medication combined) | | SURMOUNT-OSA | Obesity + moderate–severe OSA | AHI reduced by 63%; 42% achieved OSA remission — basis for 2024 FDA OSA approval | | SURMOUNT-5 (2025, NEJM) | Head-to-head vs sema 2.4mg, n=751 | Tir −20.2% vs sema −13.7% — 47% greater relative reduction; superior at every predefined weight loss threshold |

SURMOUNT-1 detail (Jastreboff et al., 2022, NEJM, n=2,539): This landmark trial enrolled adults with BMI ≥30 (or ≥27 with at least one comorbidity) without T2D, randomised to 5mg, 10mg, or 15mg tirzepatide or placebo. At 72 weeks, mean weight loss was 15.0%, 19.5%, and 20.9% for the three doses respectively, versus 3.1% for placebo. Critically, 37% of participants on 15mg lost ≥25% of their body weight — a threshold previously only seen with bariatric surgery.

SURMOUNT-5 (2025, NEJM): The first direct head-to-head comparison of tirzepatide (15mg) against semaglutide 2.4mg (the maximum obesity dose of Wegovy). At 72 weeks, tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide. Tirzepatide was superior at all predefined thresholds: ≥10%, ≥15%, ≥20%, and ≥25% body weight loss. GI tolerability also favoured tirzepatide (see Section 6).

---

4. Dosage guidance

Tirzepatide follows a mandatory escalation protocol. The starting dose of 2.5mg is for tolerability only — it has no meaningful therapeutic effect at that level. Escalation proceeds in 4-week steps, allowing the GI system to adapt.

Dosage adjustments must be made in consultation with a prescribing physician. Self-escalating beyond prescribed doses is not safe.

---

5. Administration

Route: Subcutaneous (SubQ) injection only. There is no oral tirzepatide formulation — unlike semaglutide, which has an oral tablet form (Rybelsus) for T2D. Tirzepatide is injection-only for all approved indications.

Frequency: Once weekly, same day each week. Can be taken at any time of day, with or without food. If a dose is missed by fewer than four days, inject as soon as remembered and continue the weekly schedule. If more than four days have passed, skip and resume on the next scheduled day.

Injection sites: Abdomen, upper thigh, or outer upper arm. Rotate the site each week — do not inject in the same location consecutively. Avoid areas of skin that are irritated, bruised, or hardened.

Technique: Clean the skin with an alcohol swab. Allow to dry. Pinch 2–5 cm of skin if lean. Insert at 45–90 degrees. Depress the pen cap completely and hold for 10 seconds. Confirm the dose window shows the dose has been delivered.

Storage:

• Refrigerate at 2–8°C (never freeze)
• If needed, may be stored at room temperature (≤30°C) for up to 21 days
• Protect from light and heat
• Do not use if discoloured, cloudy, or containing particles

---

6. Safety and side effects

Common side effects

The most frequent side effects are gastrointestinal, dose-dependent, and typically most pronounced during escalation. They generally improve as the body adapts.

| Side effect | Incidence (pooled SURMOUNT data) | |-------------|----------------------------------| | Nausea | 12–18% | | Diarrhoea | 12–17% | | Vomiting | 5–9% | | Constipation | 6–10% | | Abdominal pain | 5–8% |

Comparison with semaglutide: SURMOUNT-5 confirmed better GI tolerability for tirzepatide. Vomiting occurred in 9% of tirzepatide patients versus 24% on semaglutide; diarrhoea in 17% versus 30%. This difference may reflect complementary GIP signalling on gut motility or a more gradual dose-effect profile.

Practical management: Take the injection at a consistent time. Eat smaller meals. Avoid high-fat or spicy meals during the first weeks of a new dose. Stay hydrated. Most GI effects are transient and resolve within 1–2 weeks of reaching a stable dose. If vomiting or diarrhoea is severe or persistent, contact your prescriber — dose delay is preferable to stopping entirely.

Black box warning

Like all GLP-1 receptor agonists, tirzepatide carries an FDA Black Box Warning: thyroid C-cell tumours were observed in rodent studies. The relevance to humans is unknown — GLP-1 receptors are absent in human thyroid C-cells — but the warning exists across the drug class.

Tirzepatide is contraindicated in:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN2)

Other notable risks

Pancreatitis: Rare but reported. Discontinue and do not restart if acute pancreatitis is confirmed. Prior history of pancreatitis is a relative contraindication.

Cholelithiasis (gallstones): Incidence approximately 1.2% in tirzepatide groups versus 0.4% in placebo — consistent with the increased cholelithiasis risk seen with rapid weight loss agents broadly. Symptoms of biliary disease warrant assessment.

Gastroparesis: Significant gastric emptying delay at higher doses can affect absorption of oral medications. This is clinically relevant in patients on drugs with narrow therapeutic windows.

Hypoglycaemia: Low risk as monotherapy. Risk increases significantly when combined with insulin or sulfonylureas (dosage reduction of those agents is typically required, often 20–50%).

Drug interactions

| Drug class | Interaction | Action | |-----------|-------------|--------| | Insulin | Hypoglycaemia risk | Reduce insulin dose 20–50% on initiation | | Sulfonylureas (glipizide, gliclazide) | Hypoglycaemia risk | Consider dose reduction | | Oral contraceptives | Gastric emptying delay reduces absorption | Use additional barrier contraception for 4 weeks post-initiation and after each dose escalation | | Narrow therapeutic index drugs (warfarin, cyclosporine, digoxin, levothyroxine) | Variable absorption affected by gastric emptying changes | Monitor levels more closely; time dosing carefully | | Other GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) | Additive GI toxicity; no benefit | Contraindicated — do not combine | | SGLT2 inhibitors (dapagliflozin, empagliflozin) | Generally safe; complementary mechanisms | No dose adjustment typically required |

---

7. Who should consider this

Tirzepatide is a prescription medicine. The decision to use it should be made with a prescribing physician who can assess eligibility, co-prescribe safely, and monitor response.

Standard eligibility criteria

• BMI ≥30, or
• BMI ≥27 with at least one weight-related comorbidity (T2D, hypertension, dyslipidaemia, OSA, cardiovascular disease)

Tirzepatide vs semaglutide — practical decision guide

These are the two most clinically advanced GLP-1-class agents. Neither is universally "better" — the right choice depends on individual circumstances.

| Clinical profile | Preferred agent | |-----------------|----------------| | Maximum weight loss is the priority | Tirzepatide (SURMOUNT-5: −20.2% vs −13.7%) | | T2D + obesity (HbA1c + weight) | Tirzepatide (superior on both endpoints across SURPASS) | | Established cardiovascular disease, CV outcomes priority | Semaglutide (SELECT trial: 20% reduction in MACE; no equivalent tirzepatide CV outcomes data yet) | | History of GI intolerance to semaglutide | Tirzepatide (better GI tolerability profile) | | Obesity + obstructive sleep apnoea | Tirzepatide (FDA-approved for OSA; semaglutide is not) | | Oral route preferred (T2D) | Semaglutide (Rybelsus oral tablet; no oral tirzepatide exists) | | Already responding well to semaglutide | Consider continuing — switching is not always necessary |

Semaglutide note: Semaglutide has stronger cardiovascular outcomes data (the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in non-diabetic patients with established CVD and obesity). Tirzepatide's cardiovascular outcomes trial is ongoing. For patients where CV risk reduction is the primary driver — not weight loss — semaglutide currently has stronger evidence.

Not appropriate for

• Personal or family history of medullary thyroid carcinoma (MTC) or MEN2
• Pregnancy (discontinue tirzepatide at least one month before planned pregnancy)
• Type 1 diabetes
• Diagnosed gastroparesis
• Current use of another GLP-1 receptor agonist
• Patients not willing to commit to medical supervision and follow-up

---

8. Related peptides

If you're researching tirzepatide, the most relevant companion guide covers the compound it was compared against directly:

• Semaglutide — The most clinically comparable agent. Selective GLP-1 receptor agonist (Ozempic for T2D, Wegovy for obesity). Stronger cardiovascular outcomes evidence (SELECT trial). Lower mean weight loss than tirzepatide in direct comparison (SURMOUNT-5, 2025). Oral formulation available for T2D (Rybelsus). The appropriate choice depends on individual goals, medical history, and prescriber assessment — not simply which drug has better headline numbers.

---

This guide is produced for educational purposes only. Tirzepatide is a prescription-only medicine. It requires assessment, prescribing, and ongoing monitoring by a licensed healthcare provider. Nothing in this guide constitutes medical advice, and it does not replace a clinical consultation. UAE residents should seek tirzepatide only through a licensed prescriber and a MOHAP-registered pharmacy. Compounded or grey-market tirzepatide is illegal in the UAE.

---

Ready to understand where tirzepatide fits your goals?

Take the SEQUENCE quiz to receive a personalised protocol overview based on your specific health objectives, experience level, and what you're trying to achieve.